Last data update: May 06, 2024. (Total: 46732 publications since 2009)
Records 1-1 (of 1 Records) |
Query Trace: Mathis AL[original query] |
---|
COVID-19 Investigational Treatments in Use Among Hospitalized Patients Identified Through the US Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, March 1-June 30, 2020.
Acosta AM , Mathis AL , Budnitz DS , Geller AI , Chai SJ , Alden NB , Meek J , Anderson EJ , Ryan P , Kim S , Como-Sabetti K , Torres S , Dufort E , Bennett NM , Billing LM , Sutton M , Keipp Talbot H , George A , Pham H , Hall AJ , Fry A , Garg S , Kim L . Open Forum Infect Dis 2020 7 (11) ofaa528 Using a coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network, we found that 42.5% of hospitalized COVID-19 cases with available data from March 1-June 30, 2020, received ≥1 COVID-19 investigational treatment. Hydroxychloroquine, azithromycin, and remdesivir were used frequently; however, hydroxychloroquine and azithromycin use declined over time, while use of remdesivir increased. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 06, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure